Uploaded October 2022 | Updated November 2026, 3 hours ago
By extracting human immune cells and genetically reprogramming them to hunt cancer cells, CAR-T therapy changed the treatment paradigm for patients with certain blood cancers.
How do we drive forward the next generation of this potentially transformative technology? At Novartis, we’re developing our T-Charge platform as a foundation to build future CAR-T therapies that can address more of the challenges that cancers pose.
Learn more: bit.ly/3gIGxEZ
©2022 Novartis AG
By extracting human immune cells and genetically reprogramming them to hunt cancer cells, CAR-T therapy changed the treatment paradigm for patients with certain blood cancers.
How do we drive forward the next generation of this potentially transformative technology? At Novartis, we’re developing our T-Charge platform as a foundation to build future CAR-T therapies that can address more of the challenges that cancers pose.
Learn more: bit.ly/3gIGxEZ
©2022 Novartis AG










